Prescription & Enrollment Form

Multiple Sclerosis (T-Z)



Honolulu, HI 96813-5412

1 PATIENT INFORM.	ATION	□ Nev	v patient 🗅 Current
Patient's first name			
Last name			Middle initial
Date of birth	☐ Male ☐ Female	Last 4 digits o	f SSN
Street address			Apt #
City		State	Zip
Parent/guardian (if applicable)			
Cell phone	Other phor	ne	
E-mail address			
Patient's primary language: 🖵 Engli	ish 🗆 Other If othe	r, please specif	y
Please attach copies of front and back	of patient's insuranc	e cards or comp	lete information below.
Insurance company		Phone	
Insured's name			
Insured's employer			
Relationship to patient			
Identification #			
Policy/group #			
Prescription card: ☐ Yes ☐ No If ye	s, carrier		
Policy#			
Group #			
Is patient eligible for Medicare? \square Y			
Does patient have a secondary insu	rance? ☐ Yes ☐ No		

Four simple steps to submit your referral.

2 PRESCRIB	ER INFORM	ATION	All fields must be completed to expedite prescription fulfillment
Date	Time	Date n	nedication needed:
Deliver product to: \Box	Office 🗖 Patient's h	nome 🗆 Clinic	
Prescriber's first name	2	Las	t name
Prescriber's title			
If NP or PA, under dire	ction of Dr		
Office contact and tit	le		
Office contact e-mail			
Clinic/hospital location	on		
Street address			Suite #
City		State	Zip
Phone			
NPI#			ise #

Primary ICD-10 code:		
Laboratory results: LEVF		Date
Platelets		Date
ANC		Date
Pregnancy test	_(+/-)	Date
Bilirubinmg/dL Patient weight		Date
EXPECTED DATE OF FIRST/NEXT INJECTION	_	
DATE OF LAST INJECTION (if applicable)		
Agency nurse to visit home for injection: ☐ Yes ☐ No		
Agency name & phone		
□ NKDA □ Known drug allergies		
Concurrent meds		

Medication	Strength/Formulation	Directions	Quantity/Refills				
Tysabri® (natalizumab)	Tysabri® is available only through the TOUCH™ Prescribing Program. Please call 800.456.2255 or go to www.tysabri.com.						
□ Vumerity™ (diroximel fumarate)	231mg delayed-release capsules	☐ Starting dose: take 231mg capsule twice a day for 7 days. ☐ Maintenance dose after 7 days: 462mg (administered as two 231mg capsules) twice a day, orally.	Supply: □ 30-day □ 90-day □ Other Refills				
□ Zeposia® □ Starter Kit (therapy initiation) (four 0.23mg and three 0.46mg and thirty 0.92mg capsules)		☐ Take one 0.23mg capsule daily for 4 days, then one 0.46mg capsule daily for 3 days, then one 0.92mg capsule daily thereafter.	☐ 4 week supply (1 kit) No refills				
	□ 0.92mg capsule (maintenance)	☐ Take one capsule daily.	☐ 30 capsules = 30-days (1 bottle) Refills				
☐ Starter pack (re-titration only) (four 0.23mg and three 0.46mg capsules)		☐ Take one 0.23mg capsule daily for 4 days, then one 0.46mg capsule daily for 3 days.	☐ 7-day supply (1 pack) No refills				
		□ Other:					
Other:			Supply: □30-day □90-day □ OtherRefills				
	ck here to authorize ancillary supplies such as needles, office, physician accepts on behalf of patient for admin	syringes, sterile water, etc. to administer therapy as needed istration in office.	•				
	y that the above therapy is medically necessary. I also a such health plans, to the extent not prohibited.	uthorize Accredo to initiate any de minimus authorization processes from applicable health plans, if need					
Prescriber's signature (si	gn below) (Physician attests this is his/her legal signat	PHYSICIAN SIGNATURE RE	QUIKED				
Date	Dispense as written	Date Substitution allowed					

Please fax completed form to 808.650.6487.

To reach your team, call toll-free 808.650.6488.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.